Home
overview
‘The best antibacterial conference’
Ines Holzbaur, Genechem Therapeutics Venture Fund

A unique opportunity to learn from leading industry experts including:

  • Dr Beat Weidmann, Head, Infectious Diseases, Preclinical Research, Novartis Pharmaceuticals
  • Dr Julie Strizki, Associate Principal Scientist, Schering-Plough
  • Dr William Weiss, Principle Research Scientist, Wyeth-Ayerst Research
  • Dr Mick Black, Director Molecular Biology, Infectious Diseases, Aventis
  • Dr Richard Bax, Vice President & Chief Scientific Officer, Biosyn
  • Dr Mark Nelson, Senior Director, Chemistry, Paratek Pharmaceuticals
  • Dr Gordon Foulkes, Executive Vice President, Research & Development, Elitra Pharmaceuticals
  • Dr Malcolm Page, Head, Discovery Biology, Basilea Pharmaceutica

A two day intensive conference which will help you:

  • KEEP up with the latest developments in the Anti Infective market
  • LEARN from the leading experts in the field
  • IMPROVE your knowledge of the industry
  • MEET key industry decision makers
  • TAKE advantage of the networking opportunities

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Dr Richard Bax

Dr Richard Bax, Vice President & Chief Scientific Officer, Biosyn

9:10 Superbugs: The Scope Of The Problem

Dr Jeffrey Stein

Dr Jeffrey Stein, Chief Scientific Officer, Quorex Pharmaceuticals

  • Re-emerging infectious diseases
  • Emerging therapies to address the issue of resistance
  • New approaches to overcome virulence & resistance
  • 9:40 Better Medicines

    Dr Richard Bax

    Dr Richard Bax, Vice President & Chief Scientific Officer, Biosyn

  • Novel targeted delivery for prevention and treatment of infectious diseases
  • Broad acting non-antibiotic microbicide (C31G), active against bacteria, fungi and viruses
  • Specific anti-HIV products, cyanovirin-N (protein) and UC781 (NNRTI)
  • Topical use to prevent sexually transmitted disease (HIV, Chlamydia, HSV)
  • Dermatological, oral and ophthalmic use for both Rx and prevention
  • Strategic focus on both developing HIV and developed world needs (Chlamydia, Candida, HSV, Staph. & Strep.)
  • 10:20 Novel Approaches To Treating & Preventing Infection

    Dr Malcolm Page

    Dr Malcolm Page, Head, Discovery Biology, Basilea Pharmaceutica

  • Current technology strategies
  • Combating and exploiting resistance
  • High throughput screening
  • Integrated technology platforms for discovery of novel anti-infectives
  • Cost effectiveness
  • Future technological developments
  • 11:00 Morning Coffee

    11:20 Developing Antimicrobial Peptides

    Dr Hans-Henrik Kristensen Hogenhaug

    Dr Hans-Henrik Kristensen Hogenhaug, Manager, Novozymes

  • Novozymes technology platform in the anti- infective area
  • Identification of novel antimicrobial peptides
  • Optimisation of lead antimicrobial peptides using HTP screening & selection systems
  • Economically viable recombinant production strategies
  • Pre-clinical data on selected lead molecules
  • 12:00 Postgenomic Approaches To Antiinfective Drug Discovery

    Dr Ken Powell

    Dr Ken Powell, Chief Executive Officer, Arrow Therapeutics

  • Essential gene identification - what does essential mean?
  • Target validation-the rigorous approach
  • Finding the starting point for medicinal chemistry
  • Applying protein structure and function to drug design
  • Moving from the lead to the preclinical candidate
  • Antiinfective drug development
    Partnerships in clinical development
  • 12:40 Lunch

    14:00 From Genes To Drugs

    Dr Beat Weidmann

    Dr Beat Weidmann, Head, Infectious Diseases, Preclinical Research, Novartis Pharmaceuticals

  • Identifying essential gene drug targets
  • The use of genomics in antibacterial drug discovery
  • Target validation through functional genomics/genetics
  • Impact of technology
  • Speeding up drug development
  • New anti infectives in early stages
  • 14:40 Antimicrobial Drug Discovery - Genes To Leads & Leads To Genes’

    Dr Gordon Foulkes

    Dr Gordon Foulkes, Executive Vice President, Research and Development, Elitra Pharmaceuticals

  • There is an urgent need to develop novel antimicrobial drugs against novel drug targets to combat the growing problem of drug resistance.
  • Elitra is employing proprietary ultra-rapid methods for essential gene identification in major pathogenic bacterial and fungal pathogens.
  • We have filed patents on over 4000 essential gene targets
  • Drug screens can be developed for any validated target in the database within 2-3 weeks
  • Identification of ‘all’ essential genes allows the development of genome wide target ‘BioArrays’ and the rapid identification of the targets of antimicrobial compounds of unknown mechanism.
  • 15:20 Afternoon Tea

    15:40 Novel Genomic Targets For Novel Antimicrobials

    Dr Mick Black

    Dr Mick Black, Director Molecular Biology, Infectious Diseases, Aventis

  • The promise of genomics
  • Status of microbial genomes
  • Missing genes and FUN genes
  • What is ‘functional analysis’?
  • 16:20 Antimicrobial Chemotherapy

    Dr William Weiss

    Dr William Weiss, Principal Research Scientist, Wyeth Ayerst

  • Target selection and validation
  • Substructure searches and compound selection
  • Activity/efficacy evaluation
  • Biological feedback to synthetic chemistry synthesis
  • Lead selection process
  • The go/no go decision
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    9:10 Emerging Therapies For HIV Infection

    Dr Julie Strizki

    Dr Julie Strizki, Associate Principal Scientist, Schering-Plough

  • The need for more potent and less toxic therapies
  • Targeting the viral glycoproteins
  • Novel peptide inhibitors of viral fusion
  • Development of coreceptor antagonists with antiviral activity
  • Potential consequences of viral resistance
  • Prophylactic use of entry inhibitors to prevent infection
  • 9:40 Novel Antisense Therapies For Emerging Infectious Disease

    Prof Patrick Iversen

    Prof Patrick Iversen, Senior Vice President, Research & Development, AVI BioPharma

  • Human disease from caliciviridae vesivirus
  • Non A-E hepatitis
  • Zoonotic virus
  • Viral induced abortion
  • Hemorrhagic viral infection
  • 10:20 A New Approach To Fungal Therapeutics

    Dr Eric Summers

    Dr Eric Summers, Founder & Senior Principal Clinical Investigator, Microbia

  • The need for novel nontoxic antifungal approaches
  • A new concept in antifungals
  • Predicting efficacy In vivo
  • Identifying and evaluating activities In vitro
  • Improving antifungal therapeutics
  • Expanding the application of antifungal prophylaxis
  • 11:00 Morning Coffee

    11:20 Genomics Based Mode Of Action (MOA) Analysis Of Antibacterial Compounds

    Hannes Loferer

    Hannes Loferer, Senior Director, Microbiology, GPC Biotech

  • GPC Biotech’s ExpressCode™ technology
  • Analysing the effect of antibacterial compound treatment on bacterial gene expression profiles
  • Establishing a reference data set with antibiotics of known MOA
  • MOA categorisation of compounds by means of clustering analysis
  • 12:00 GD PHYLOSOPHER™

    Dr Hans Peter Fischer

    Dr Hans Peter Fischer, Chief Scientific Officer, GeneData

  • Antibiotics target finding and prioritisation: combining large scale genome and transcriptome analyses
  • Functional characterisation of target candidates: from sequences to assays
  • Integration of chemical data, e.g. inhibitor databases into analysis process
  • Automated mode-of-action classification of novel structural classes of small molecule inhibitors
  • Effect of antimicrobials on a pathogen’s genetic regulatory networks and mRNA profile correlations
  • Automated identification of stress inducible promoters for MOA specific cellular assays
  • 12:40 Lunch

    14:00 Resurgent Microbial Pathogens and Novel Approaches to Chemotherapy

    Dr Mark Nelson

    Dr Mark Nelson, Senior Director, Chemistry, Paratek Pharmaceuticals

  • Bacteria and pathogenic mechanisms of resistance
  • Current novel approaches to antibacterial chemotherapy
  • Paratek Pharmaceuticals and the development of novel tetracyclines against resurgent pathogens
  • Other microbial targets and technologies progressing at Paratek
  • 14:40 Lamectacins & Formylectacins: Enzyme-Activated Therapeutics

    Dr Michael Shepard

    Dr Michael Shepard, President & Chief Scientific Officer, NewBiotics

  • Introduction to ECTA technology
  • Lamectacins: proof of principle
  • In vitro antibacterial activity
  • Efficacy in animal models of infection
  • Formylectacins: proof of principle
  • In vitro antibacterial activity
    Efficacy in animal models of infection
    Conclusions and future directions
  • 15:20 Afternoon Tea

    15:40 Novel Methods To Screen Antibacterial Targets Of Unknown Function And Difficult To Assay Targets

    Dr Dale Christensen

    Dr Dale Christensen, Senior Scientist, Karo Bio

  • Identification of surrogate ligand probes using phage display
  • Validation of peptide probes
  • Screening formats for HTS
  • Results from HTS for difficult to assay targets
  • Correlation of biochemical assays and surrogate ligand-based assays
  • 16:20 Novel Approach For Prophlaxis Of Infections

    Per Fischer

    Per Fischer, President & Chief Executive Officer, NatImmune

  • Role of MBL in normal host defence
  • MBL deficiencies - diagnosis and prevalence
  • Correlation of MBL deficiency with susceptibility to infections and disease
  • Development of recombinant MBL for replacement therapy
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.